Does Network Health Cover Forteo (Teriparatide)?

What Is Forteo and Why Does It Require Special Insurance Review?

Forteo is a brand-name anabolic bone agent. Most osteoporosis drugs suppress bone resorption; teriparatide does the opposite, stimulating new bone formation by activating PTH receptor 1 on osteoblasts. That mechanism produces faster and larger BMD gains than bisphosphonates, but the drug costs roughly 40 times more per year than generic alendronate.

Because of that cost gap, Network Health and most other U.S. Insurers classify Forteo as a specialty medication subject to clinical review. The FDA approved teriparatide in 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis [1]. The label carries a black-box warning about osteosarcoma observed in rat studies at supraphysiologic doses; the warning restricts lifetime use to 2 years [1].

How Teriparatide Works Clinically

In the key Neer et al. Trial (N=1,637), teriparatide 20 mcg daily for a median of 19 months reduced new vertebral fractures by 65% (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and nonvertebral fragility fractures by 53% compared with placebo [2]. Lumbar spine BMD rose 9.7% and femoral neck BMD rose 2.8% versus placebo at 18 months [2]. These data are what prescribers cite in prior-authorization letters when bisphosphonate therapy has failed or is contraindicated.

Where Forteo Sits on the Network Health Formulary

Network Health operates primarily in Wisconsin and offers commercial, Medicare Advantage, and Marketplace plans. Across plan types, teriparatide consistently lands on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty). Tier placement affects cost-sharing: Tier 4 copays on commercial plans typically run $150, $300 per fill, while Tier 5 can reach 25 to 30% coinsurance before the out-of-pocket maximum. Members should pull the current Summary of Benefits and Coverage (SBC) directly from Network Health's member portal because formulary tiers are updated annually in October for the following plan year.

Prior Authorization Criteria Network Health Applies to Forteo

Prior authorization for teriparatide follows criteria that align closely with guidelines from the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society. Network Health's internal criteria are not always published verbatim, but criteria from comparable regional insurers and publicly available AACE guidance [3] point to the following requirements.

Diagnosis and Fracture-Risk Documentation

The prescribing clinician must document one of the following:

• A T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip on dual-energy X-ray absorptiometry (DXA)
• A T-score between -1.0 and -2.5 combined with a 10-year major osteoporotic fracture probability of 20% or higher on FRAX, or a hip fracture probability of 3% or higher [4]
• A low-trauma fracture at the spine or hip, regardless of T-score

The AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis (2020) state: "Teriparatide and abaloparatide are recommended for patients with severe osteoporosis, including those who have experienced a fracture on antiresorptive therapy" [3]. That sentence appears verbatim in many prior-auth decision letters as the clinical rationale.

Step Therapy: The Bisphosphonate Requirement

Network Health, like most commercial payers, requires documented failure, intolerance, or contraindication to at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) before approving teriparatide. Failure is typically defined as:

• Ongoing bone loss (BMD decrease exceeding the least significant change, usually 3 to 5%) despite 12 months of therapy at an adequate dose
• A new fragility fracture while on therapy
• Documented intolerance (esophageal adverse events, severe GI symptoms)
• Medical contraindication such as creatinine clearance <35 mL/min, which precludes oral bisphosphonate use per the prescribing information [5]

If intravenous zoledronic acid (Reclast 5 mg annually) was used instead and failed, that typically satisfies the step-therapy requirement as well.

Duration and Renewal Criteria

Initial approval is usually granted for 6 months. Renewals require documentation of tolerability and, ideally, a follow-up DXA showing stable or improved BMD. The FDA label caps lifetime teriparatide use at 2 years [1], so insurers will not approve beyond that cumulative window regardless of clinical rationale.

How to Get Forteo Approved Through Network Health

Approval rates improve substantially when the prescribing team submits a complete, well-documented prior-authorization packet on the first submission rather than waiting for a denial and appeal.

Building a Strong Prior-Authorization Letter

A strong letter should include:

1. The patient's most recent DXA report with T-scores at all sites measured
2. FRAX score calculation (available at sheffield.ac.uk/FRAX, though that URL is outside the allow-list; the CDC references FRAX as the validated tool for U.S. Fracture risk assessment [6])
3. Documentation of bisphosphonate trial: drug name, dose, duration, reason for discontinuation or failure
4. Fracture history with imaging reports if applicable
5. Direct quotation of the relevant AACE/ACE guideline recommendation [3]
6. Serum calcium and 25-hydroxyvitamin D levels confirming the patient is replete (calcium <10.5 mg/dL and 25-OHD above 30 ng/mL are typically required before anabolic therapy)

The Appeals Process When Coverage Is Denied

If Network Health denies the initial request, Wisconsin state law (and federal ACA rules) guarantees the right to an internal appeal and, if that fails, an independent external review. The external review organization must be accredited and apply clinical criteria independent of the insurer. For Medicare Advantage denials, the process follows CMS guidelines [7], and timelines are strictly regulated: standard appeals must be decided within 60 days; expedited appeals within 72 hours when a delay would seriously jeopardize health.

The HealthRX Prior-Auth Success Framework for Teriparatide outlines a three-step submission sequence: (1) submit a complete packet with DXA, FRAX, and step-therapy documentation simultaneously rather than sequentially; (2) request a peer-to-peer call with the medical director within 5 business days if an initial denial arrives; (3) file the internal appeal with a supporting letter from an endocrinologist or rheumatologist citing the AACE 2020 guideline Grade A recommendation for anabolic therapy in severe osteoporosis [3]. Practices using this sequence at HealthRX report first-pass approval rates above 70% for teriparatide.

Forteo Cost Without Insurance and Assistance Programs

Even with coverage, specialty cost-sharing can be a barrier. The 2024 wholesale acquisition cost (WAC) for one Forteo pen (28-day supply, 20 mcg/dose) is approximately $2,700, $3,100 depending on the pharmacy [8]. Annual spend approaches $35,000 at list price.

Eli Lilly Assistance Programs

Eli Lilly offers two pathways:

• Lilly Cares Foundation: For uninsured or underinsured patients with household income at or below 400% of the federal poverty level, Forteo may be available at no cost.
• Lilly Insulin Value Program / commercial copay card: Eligible commercially insured patients may pay as little as $25, $50 per month. Medicare Part D patients are excluded from commercial copay card programs under federal anti-kickback rules [9].

State Pharmaceutical Assistance Programs

Wisconsin's SeniorCare program provides drug coverage to residents aged 65 and older who meet income thresholds. SeniorCare enrollees who are not yet eligible for Medicare Part D may find teriparatide more accessible through that program. Contact the Wisconsin Department of Health Services for current eligibility criteria.

Biosimilar and Alternative Anabolic Options

The FDA approved Bonsity (teriparatide-aazt, Alvogen) in 2021 as a biosimilar to Forteo [10]. Biosimilars typically launch at 15 to 35% below the reference drug's list price. Some Network Health formularies prefer Bonsity over brand Forteo when an anabolic PTH agent is authorized, so checking the current formulary before submitting a prior-auth for brand Forteo specifically can save a denial and resubmission cycle.

Abaloparatide (Tymlos, Radius Health) is a PTH-related protein analog, not a biosimilar, approved in 2017 [11]. The ACTIVExtend trial showed abaloparatide 80 mcg daily reduced vertebral fracture risk by 86% versus placebo at 18 months (N=2,463, P<0.001) [12]. Some Network Health formularies tier Tymlos at a lower specialty tier than Forteo, making it a clinically equivalent option with lower cost-sharing in certain plan years.

Clinical Guidelines Governing Teriparatide Prescribing

Understanding the guideline field helps clinicians justify teriparatide and helps patients understand why their doctor is recommending it.

AACE/ACE 2020 Postmenopausal Osteoporosis Guidelines

The AACE/ACE 2020 guidelines recommend anabolic agents (teriparatide or abaloparatide) as first-line therapy for patients with very high fracture risk, defined as a T-score below -3.0, multiple prior vertebral fractures, or fracture on antiresorptive therapy [3]. The guidelines assign this recommendation Grade A, meaning it is supported by strong evidence from randomized controlled trials.

Endocrine Society Clinical Practice Guideline

The Endocrine Society's 2019 pharmacological management guideline recommends teriparatide for postmenopausal women with osteoporosis and high fracture risk, particularly those with spine involvement, and notes that sequential therapy with an antiresorptive agent after completing teriparatide is necessary to preserve BMD gains [13]. Without follow-on bisphosphonate or denosumab therapy, BMD can decline toward baseline within 12 to 18 months after stopping teriparatide [13].

NOF/BHOF Clinician's Guide

The Bone Health and Osteoporosis Foundation (BHOF) Clinician's Guide supports teriparatide use in patients with high fracture risk and explicitly recommends against limiting anabolic therapy to patients who have failed antiresorptive therapy when the clinical picture warrants immediate anabolic treatment [4]. This point is worth citing in a prior-auth letter when Network Health's step-therapy requirement seems clinically inappropriate for a given patient.

Forteo vs. Romosozumab: Choosing the Right Anabolic Agent

For patients with very high fracture risk, prescribers sometimes consider romosozumab (Evenity, Amgen) instead of teriparatide. Romosozumab is a sclerostin inhibitor that both stimulates bone formation and reduces bone resorption. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% and hip fracture risk by 23% versus alendronate alone over 24 months [14]. Network Health coverage for romosozumab follows similar prior-authorization logic to teriparatide.

Key Differences in Coverage Logic

Romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death, and is contraindicated within 12 months of a cardiac event [14]. Network Health prior-auth criteria for romosozumab therefore include cardiovascular screening documentation not required for teriparatide. Patients with a recent MI or stroke are typically steered toward teriparatide rather than romosozumab.

Teriparatide remains the default anabolic choice on most Network Health formularies for patients without cardiovascular contraindications who meet fracture-risk thresholds, primarily because of the longer safety and efficacy track record since 2002 [1][2].

Monitoring Requirements During Teriparatide Therapy

Network Health renewal authorizations typically require evidence of clinical monitoring. The Endocrine Society recommends the following monitoring schedule during teriparatide therapy [13]:

• Serum calcium 1 to 4 weeks after initiation (teriparatide transiently raises serum calcium; hypercalcemia occurs in approximately 11% of patients at some point during therapy)
• Repeat DXA at 18 to 24 months to document response
• Serum 25-hydroxyvitamin D and urinary calcium before initiating therapy

Vitamin D and Calcium Adequacy

The National Osteoporosis Foundation recommends 1,000 to 1,200 mg elemental calcium daily from diet plus supplements combined, and 800 to 1,000 IU vitamin D3 daily for adults over 50 [4]. Teriparatide's efficacy depends on adequate calcium and vitamin D status; the key Neer trial provided all participants with 1,000 mg calcium and 400 to 1,200 IU vitamin D as supplements throughout the study [2]. Patients who are deficient at baseline should be repleted before initiating anabolic therapy.

Post-Teriparatide Antiresorptive Therapy

Completing 2 years of teriparatide without a sequential antiresorptive agent wastes most of the BMD gain. The DATA-Switch trial (N=94) demonstrated that transitioning from teriparatide to denosumab (Prolia 60 mg every 6 months) produced continued BMD increases of 6.6% at the spine and 2.9% at the hip over 24 additional months, versus BMD decline in the group that received no follow-on therapy [15]. Network Health typically covers denosumab under a separate prior authorization, and that request should be submitted before teriparatide therapy ends to avoid a coverage gap.

Practical Steps for Network Health Members Seeking Forteo Coverage

Getting coverage approved involves the prescriber, the pharmacy, and the patient working in parallel rather than sequentially.

Step 1: Confirm Your Plan Year Formulary

Network Health posts updated formularies each November for the following plan year. Log into the member portal, download the current drug list, and confirm Forteo's tier and any quantity limits. If Bonsity (the biosimilar) appears at a lower tier, discuss substitution with your prescriber.

Step 2: Ask Your Prescriber to Use a Specialty Pharmacy

Most Network Health plans require specialty medications to be dispensed through a contracted specialty pharmacy rather than a retail location. Forteo requires refrigeration (36 to 46°F) and is dispensed as a prefilled, multi-dose injection pen. Specialty pharmacies provide injection training, temperature-controlled shipping, and often have dedicated prior-auth teams.

Step 3: Apply for Financial Assistance Before Your First Fill

Submit the Lilly Cares application and the commercial copay card application simultaneously with the prior-auth process, not after approval. Processing times for patient-assistance programs can run 2 to 4 weeks, and having assistance confirmed before the first fill prevents an unexpected $2,700 pharmacy bill.

Step 4: Know Your Appeal Rights

Under Wisconsin state law and the ACA, you have the right to appeal any adverse coverage determination. Keep copies of every document submitted, note the date and name of every phone call with Network Health, and request a written explanation of any denial. The written denial must cite the specific clinical criteria used, which gives you the precise language to address in an appeal.